Glycoprotein exhibiting immunological and enzymatic activities of human prostatic acid phosphatase

Ming Fong Lin, Ching Li Lee, T. Ming Chu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A glycoprotein (GP) which is immunochemically and biologically related to human prostatic acid phosphatase (PAP) has been isolated from human seminal plasma by ammonium sulfate precipitation followed by sequential concanavalin A:Sepharose 4B column, anion-exchange chromatography and gel filtration. The purified GP was shown to be homogeneous by disc-and sodium dodecyl sulfate.poiyacrylamide gel electrophoresis. The apparent molecular weight of purified GP was estimated to be 50,000 by gel filtration and 45,000 by sodium dodecyl sulfate:gel electrophoresis. In gel diffusion against antiserum to purified PAP, a partial immunological identity was shown between GP and PAP. This was further confirmed by an inhibition reaction between GP and antiserum to purified GP by PAP. Significantly, 30% of PAP enzyme activity was inhibited by anti-GP antiserum, while only 5% was inhibited by anti-PAP antiserum. Purified GP was shown to exhibit a weak, but significant, acid phosphatase activity by hydrolyzing α-naphthyl phosphate at pH 5.6. The Km and Vmax for GP are 1.6×10-4 M and 0.056 μmol/min/μg protein, respectively, using α-naphthyl phosphate as the substrate. In the presence of anti-PAP antibody, the enzyme activity of GP was enhanced severalfold. Furthermore, the acid phosphatase activity of GP also was inhibited by tartrate, which is the most commonly used inhibitor for PAP. GP and PAP were found to have different carbohydrate content, amino acid composition, amino-terminal sequence, and peptide map. Thus, GP represents a newly identified protein. The significance of these results at molecular and clinical levels is discussed.

Original languageEnglish (US)
Pages (from-to)3841-3846
Number of pages6
JournalCancer Research
Volume43
Issue number8
StatePublished - Aug 1 1983

Fingerprint

Human Activities
Glycoproteins
Immune Sera
Gels
Acid Phosphatase
Sodium Dodecyl Sulfate
prostatic acid phosphatase
Gel Chromatography
Electrophoresis
Ammonium Sulfate
Enzymes
Semen
Sepharose
Anions
Proteins
Molecular Weight
Carbohydrates
Amino Acids

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Glycoprotein exhibiting immunological and enzymatic activities of human prostatic acid phosphatase. / Lin, Ming Fong; Lee, Ching Li; Chu, T. Ming.

In: Cancer Research, Vol. 43, No. 8, 01.08.1983, p. 3841-3846.

Research output: Contribution to journalArticle

@article{ffb291881f28435cbb413eff864098e1,
title = "Glycoprotein exhibiting immunological and enzymatic activities of human prostatic acid phosphatase",
abstract = "A glycoprotein (GP) which is immunochemically and biologically related to human prostatic acid phosphatase (PAP) has been isolated from human seminal plasma by ammonium sulfate precipitation followed by sequential concanavalin A:Sepharose 4B column, anion-exchange chromatography and gel filtration. The purified GP was shown to be homogeneous by disc-and sodium dodecyl sulfate.poiyacrylamide gel electrophoresis. The apparent molecular weight of purified GP was estimated to be 50,000 by gel filtration and 45,000 by sodium dodecyl sulfate:gel electrophoresis. In gel diffusion against antiserum to purified PAP, a partial immunological identity was shown between GP and PAP. This was further confirmed by an inhibition reaction between GP and antiserum to purified GP by PAP. Significantly, 30{\%} of PAP enzyme activity was inhibited by anti-GP antiserum, while only 5{\%} was inhibited by anti-PAP antiserum. Purified GP was shown to exhibit a weak, but significant, acid phosphatase activity by hydrolyzing α-naphthyl phosphate at pH 5.6. The Km and Vmax for GP are 1.6×10-4 M and 0.056 μmol/min/μg protein, respectively, using α-naphthyl phosphate as the substrate. In the presence of anti-PAP antibody, the enzyme activity of GP was enhanced severalfold. Furthermore, the acid phosphatase activity of GP also was inhibited by tartrate, which is the most commonly used inhibitor for PAP. GP and PAP were found to have different carbohydrate content, amino acid composition, amino-terminal sequence, and peptide map. Thus, GP represents a newly identified protein. The significance of these results at molecular and clinical levels is discussed.",
author = "Lin, {Ming Fong} and Lee, {Ching Li} and Chu, {T. Ming}",
year = "1983",
month = "8",
day = "1",
language = "English (US)",
volume = "43",
pages = "3841--3846",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Glycoprotein exhibiting immunological and enzymatic activities of human prostatic acid phosphatase

AU - Lin, Ming Fong

AU - Lee, Ching Li

AU - Chu, T. Ming

PY - 1983/8/1

Y1 - 1983/8/1

N2 - A glycoprotein (GP) which is immunochemically and biologically related to human prostatic acid phosphatase (PAP) has been isolated from human seminal plasma by ammonium sulfate precipitation followed by sequential concanavalin A:Sepharose 4B column, anion-exchange chromatography and gel filtration. The purified GP was shown to be homogeneous by disc-and sodium dodecyl sulfate.poiyacrylamide gel electrophoresis. The apparent molecular weight of purified GP was estimated to be 50,000 by gel filtration and 45,000 by sodium dodecyl sulfate:gel electrophoresis. In gel diffusion against antiserum to purified PAP, a partial immunological identity was shown between GP and PAP. This was further confirmed by an inhibition reaction between GP and antiserum to purified GP by PAP. Significantly, 30% of PAP enzyme activity was inhibited by anti-GP antiserum, while only 5% was inhibited by anti-PAP antiserum. Purified GP was shown to exhibit a weak, but significant, acid phosphatase activity by hydrolyzing α-naphthyl phosphate at pH 5.6. The Km and Vmax for GP are 1.6×10-4 M and 0.056 μmol/min/μg protein, respectively, using α-naphthyl phosphate as the substrate. In the presence of anti-PAP antibody, the enzyme activity of GP was enhanced severalfold. Furthermore, the acid phosphatase activity of GP also was inhibited by tartrate, which is the most commonly used inhibitor for PAP. GP and PAP were found to have different carbohydrate content, amino acid composition, amino-terminal sequence, and peptide map. Thus, GP represents a newly identified protein. The significance of these results at molecular and clinical levels is discussed.

AB - A glycoprotein (GP) which is immunochemically and biologically related to human prostatic acid phosphatase (PAP) has been isolated from human seminal plasma by ammonium sulfate precipitation followed by sequential concanavalin A:Sepharose 4B column, anion-exchange chromatography and gel filtration. The purified GP was shown to be homogeneous by disc-and sodium dodecyl sulfate.poiyacrylamide gel electrophoresis. The apparent molecular weight of purified GP was estimated to be 50,000 by gel filtration and 45,000 by sodium dodecyl sulfate:gel electrophoresis. In gel diffusion against antiserum to purified PAP, a partial immunological identity was shown between GP and PAP. This was further confirmed by an inhibition reaction between GP and antiserum to purified GP by PAP. Significantly, 30% of PAP enzyme activity was inhibited by anti-GP antiserum, while only 5% was inhibited by anti-PAP antiserum. Purified GP was shown to exhibit a weak, but significant, acid phosphatase activity by hydrolyzing α-naphthyl phosphate at pH 5.6. The Km and Vmax for GP are 1.6×10-4 M and 0.056 μmol/min/μg protein, respectively, using α-naphthyl phosphate as the substrate. In the presence of anti-PAP antibody, the enzyme activity of GP was enhanced severalfold. Furthermore, the acid phosphatase activity of GP also was inhibited by tartrate, which is the most commonly used inhibitor for PAP. GP and PAP were found to have different carbohydrate content, amino acid composition, amino-terminal sequence, and peptide map. Thus, GP represents a newly identified protein. The significance of these results at molecular and clinical levels is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0020524082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020524082&partnerID=8YFLogxK

M3 - Article

C2 - 6861148

AN - SCOPUS:0020524082

VL - 43

SP - 3841

EP - 3846

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -